Page last updated: 2024-08-24

triazoles and dasatinib

triazoles has been researched along with dasatinib in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (9.09)	29.6817
2010's	6 (54.55)	24.3611
2020's	4 (36.36)	2.80

Authors

Authors	Studies
Scheinfeld, N	1
Bovée, JV; Bruijn, IH; Hogendoorn, PC; Schrage, YM; Szuhai, K; Willems, SM	1
Chakravarty, D; Challa, R; Cortez, V; Nair, BC; Tekmal, RR; Vadlamudi, RK; Vallabhaneni, S	1
Craig, AW; Everingham, S; Kapur, R; Sharma, N; Zeng, LF; Zhang, ZY	1
Asahina, H; Beauchamp, EM; Buczkowski, KA; Hammerman, PS; Li, YY; Meyerson, M; Terai, H; Wong, KK; Xu, C; Zhang, Y	1
Bai, CG; Chen, Y; He, DD; Li, HY; Sun, TY; Zhang, Q; Zhao, XJ	1
Jiao, B; Li, D; Liao, L; Liu, M; Liu, P; Ren, R; Wang, P; Xia, Z; Xiao, X; Zhang, X	1
Cheng, G; Huang, L; Li, T; Luo, X; Xue, X; Zhang, Y	1
Lin, G; Wang, C; Wang, Y; Wen, C; Yang, S; Zhang, X; Zhou, Z	1
Brittain, SM; Henning, NJ; Manford, AG; McKenna, JM; Nomura, DK; Rape, M; Schirle, M; Spradlin, JN; Tallarico, JA; Zhang, E	1

Reviews

1 review(s) available for triazoles and dasatinib

Article	Year
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles	2007

Article

Year

A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.

Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:3

Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles

2007

Other Studies

10 other study(ies) available for triazoles and dasatinib

Article	Year
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. Molecular cancer, 2010, Sep-23, Volume: 9 Topics: Casein Kinase II; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dasatinib; HeLa Cells; Humans; Immunoblotting; Jurkat Cells; Karyotyping; Liposarcoma, Myxoid; NF-kappa B; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Triazoles	2010
Significance of ER-Src axis in hormonal therapy resistance. Breast cancer research and treatment, 2011, Volume: 130, Issue:2 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Pyrimidines; Receptor, ErbB-2; RNA Interference; src-Family Kinases; Tamoxifen; Thiazoles; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2011
Dasatinib-letrozole gets split verdict. Cancer discovery, 2014, Volume: 4, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dasatinib; Female; Humans; Letrozole; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Treatment Outcome; Triazoles	2014
Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice. Oncotarget, 2014, Aug-15, Volume: 5, Issue:15 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dasatinib; Disease Progression; Drug Synergism; Humans; Indoles; Mastocytosis, Systemic; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-kit; Signal Transduction; Triazoles	2014
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular cancer therapeutics, 2015, Volume: 14, Issue:10 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Discoidin Domain Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice, Nude; Mutation, Missense; N-Myc Proto-Oncogene Protein; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2015
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells. Bioorganic & medicinal chemistry letters, 2018, 02-15, Volume: 28, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dasatinib; Drug Design; Drug Screening Assays, Antitumor; Humans; Leukemia; Mice; Neoplastic Stem Cells; Oxadiazoles; Triazoles	2018
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. Journal of hematology & oncology, 2020, 06-18, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Animals; Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; Radiation Chimera; Random Allocation; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles	2020
Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS. Current drug metabolism, 2020, Volume: 21, Issue:13 Topics: Administration, Oral; Animals; Antifungal Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dasatinib; Drug Interactions; Drug Monitoring; Humans; Itraconazole; Ketoconazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Animal; Protein Kinase Inhibitors; Rats; Tandem Mass Spectrometry; Triazoles; Voriconazole	2020
Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats. Drug design, development and therapy, 2021, Volume: 15 Topics: Animals; Chromatography, High Pressure Liquid; Dasatinib; Equipment Design; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Triazoles	2021
Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications. Journal of the American Chemical Society, 2022, 01-19, Volume: 144, Issue:2 Topics: Acetamides; Animals; Azepines; Binding Sites; Carrier Proteins; Cell Cycle Proteins; Cell Line; Cysteine; Dasatinib; Fusion Proteins, bcr-abl; Humans; Mice; Proteasome Endopeptidase Complex; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Recombinant Proteins; Transcription Factors; Triazoles; Ubiquitin-Protein Ligase Complexes	2022